English

Roquefort Therapeutics plc

ESEF

Report (type unavailable) · filed 2025-05-20

Annual consolidated revenue for 2024: about GBP 0, using the latest reported figures. The previous period, 2023, was about GBP 200K.

Inspect reported changes Compare with another company Historical disclosures Segments

Watchlist

Latest fiscal year

Revenue

0 GBP

2024 · GBP

Exact inputs and evidence

Revenue: 0 GBP Source

Net margin

-541.73%

2021 · %

Exact inputs and evidence

Net Income: -962473 GBP Source
Revenue: 177667 GBP Source

Operating cash flow

-784 thousand GBP

2024 · GBP

Exact inputs and evidence

Operating Cash Flow: -783731 GBP Source

Free cash flow

-784 thousand GBP

2024 · GBP

Exact inputs and evidence

Operating Cash Flow: -783731 GBP Source
Capital Expenditure: 0 GBP Source

Cash and cash equivalents: 337 thousand GBP 2024-12-31 Source
Exact value

337112 GBP
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-05-20.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2024-12-31
operating income: No compatible figures in this window
Net income: 2 of 11 periods available· newest 2022-12-31
Operating cash flow: 4 of 11 periods available· newest 2024-12-31
Capital expenditure: 3 of 11 periods available· newest 2024-12-31
Total assets: 3 of 11 periods available· newest 2024-12-31
Total liabilities: 3 of 11 periods available· newest 2024-12-31
Current assets: 4 of 11 periods available· newest 2024-12-31
Current liabilities: 2 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

GBP 200,000

2023-01-01 – 2023-12-31
Current period

GBP 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 200000 = -200000 GBP

200000 GBP · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 GBP · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Roquefort Therapeutics plc · 2024-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Year-over-year change in Revenue: -200000 GBP Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 GBP (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#2849171 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 Input fundies:Revenue: 200000 GBP (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#2849376 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+GBP 949,802

Prior period

−GBP 1.73 million

2023-01-01 – 2023-12-31
Current period

−GBP 783,731

2024-01-01 – 2024-12-31

Exact inputs and evidence

-783731 − -1733533 = 949802 GBP

-1733533 GBP · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-783731 GBP · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Roquefort Therapeutics plc · 2024-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Year-over-year change in Operating cash flow: 949802 GBP Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -783731 GBP (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3071106 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 Input fundies:OperatingCashFlow: -1733533 GBP (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3071402 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

GBP 54,042

2023-01-01 – 2023-12-31
Current period

GBP 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 54042 = -54042 GBP

54042 GBP · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 GBP · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Roquefort Therapeutics plc · 2024-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Year-over-year change in Capital expenditure: -54042 GBP Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 GBP (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3072018 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 Input fundies:CapitalExpenditure: 54042 GBP (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3072350 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue GBP 0
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −GBP 783,731
Capital expenditure GBP 0
Free cash flow Derived −GBP 783,731

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	177667	Unavailable	Unavailable	Unavailable	-962473	Unavailable	Source 2021-01-01 – 2021-12-31: 177667 GBP Inspect Revenue Open source 2021-01-01 – 2021-12-31: -962473 GBP Inspect Net Income Open source 2021-01-01 – 2021-12-31: -101586 GBP Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	0	Unavailable	Unavailable	Unavailable	-177096	-1577476 Derived	Source 2022-01-01 – 2022-12-31: 0 GBP Inspect Revenue Open source 2022-01-01 – 2022-12-31: -177096 GBP Inspect Net Income Open source 2022-01-01 – 2022-12-31: -1577476 GBP Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 0 GBP Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	200000	Unavailable	Unavailable	Unavailable	Unavailable	-1787575 Derived	Source 2023-01-01 – 2023-12-31: 200000 GBP Inspect Revenue Open source 2023-01-01 – 2023-12-31: -1733533 GBP Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 54042 GBP Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	Unavailable	Unavailable	Unavailable	Unavailable	-783731 Derived	Source 2024-01-01 – 2024-12-31: 0 GBP Inspect Revenue Open source 2024-01-01 – 2024-12-31: -783731 GBP Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 GBP Inspect Capital Expenditure Open source

Amounts are exact, in GBP.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

GBP 0 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(GBP)	Source evidence
20212021-12-31	Revenue	177667	Revenue: 177667 Open source
20222022-12-31	Revenue	0	Revenue: 0 Open source
20232023-12-31	Revenue	200000	Revenue: 200000 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 177667 Open source
20222022-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 177667 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 200000 Open source Revenue: 0 Open source
20242024-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 200000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Net margin -541.7% 2021

Free cash flow margin -893.8% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2021-12-31	Operating margin	Not reported	Revenue: 177667 Open source
2022-12-31	Operating margin	Not reported	Revenue: 0 Open source
2023-12-31	Operating margin	Not reported	Revenue: 200000 Open source
2024-12-31	Operating margin	Not reported	Revenue: 0 Open source
20212021-12-31	Net margin	-541.7%	Net Income: -962473 Open source Revenue: 177667 Open source
20222022-12-31	Net margin	Not reported	Net Income: -177096 Open source Revenue: 0 Open source
2023-12-31	Net margin	Not reported	Revenue: 200000 Open source
2024-12-31	Net margin	Not reported	Revenue: 0 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 177667 Open source Operating Cash Flow: -101586 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -1577476 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow margin	-893.8%	Revenue: 200000 Open source Operating Cash Flow: -1733533 Open source Capital Expenditure: 54042 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -783731 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

GBP -783.7K 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(GBP)	Source evidence
20212021-12-31	Operating cash flow	-101586	Operating Cash Flow: -101586 Open source
20222022-12-31	Operating cash flow	-1577476	Operating Cash Flow: -1577476 Open source
20232023-12-31	Operating cash flow	-1733533	Operating Cash Flow: -1733533 Open source
20242024-12-31	Operating cash flow	-783731	Operating Cash Flow: -783731 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

GBP -783.7K 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(GBP)	Source evidence
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -101586 Open source
20222022-12-31	Free cash flow	-1577476	Operating Cash Flow: -1577476 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow	-1787575	Operating Cash Flow: -1733533 Open source Capital Expenditure: 54042 Open source
20242024-12-31	Free cash flow	-783731	Operating Cash Flow: -783731 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

15% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2021-12-31	Liabilities / assets	Not reported	No source recorded
20222022-12-31	Liabilities / assets	7.2%	Total Liabilities: 561581 Open source Total Assets: 7768217 Open source
20232023-12-31	Liabilities / assets	9.7%	Total Liabilities: 589025 Open source Total Assets: 6088568 Open source
20242024-12-31	Liabilities / assets	15%	Total Liabilities: 861726 Open source Total Assets: 5750745 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.11× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	0.14×	Current Assets: 171664 Open source Current Liabilities: 1211479 Open source
20222022-12-31	Current assets / current liabilities	2.11×	Current Assets: 2424712 Open source Current Liabilities: 1148827 Open source
20232023-12-31	Current assets / current liabilities	Not reported	Current Assets: 694911 Open source
20242024-12-31	Current assets / current liabilities	Not reported	Current Assets: 362492 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2021 2021-01-01 – 2021-12-31	−GBP 962,473 Exact value Exact value: -962473 GBP 2021-01-01 – 2021-12-31: -962473 GBP Inspect Net Income Open source Share or cite Citation for Net Income · Roquefort Therapeutics plc · 2021-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Net Income: -962473 GBP Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=GBP&dimensions= Input fundies:NetIncome: -962473 GBP (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2022-12-31/ESEF/GB/1/2138009EB25MJIULQO19-2022-12-31.zip#156343 Filing: 254900P4SISIWOR9RH34-2022-12-31-ESEF-GB-1 The citation records this snapshot. The page link may show a newer release later.	−GBP 101,586 Exact value Exact value: -101586 GBP 2021-01-01 – 2021-12-31: -101586 GBP Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Roquefort Therapeutics plc · 2021-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Operating Cash Flow: -101586 GBP Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=GBP&dimensions= Input fundies:OperatingCashFlow: -101586 GBP (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2022-12-31/ESEF/GB/1/2138009EB25MJIULQO19-2022-12-31.zip#339667 Filing: 254900P4SISIWOR9RH34-2022-12-31-ESEF-GB-1 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−GBP 177,096 Exact value Exact value: -177096 GBP 2022-01-01 – 2022-12-31: -177096 GBP Inspect Net Income Open source Share or cite Citation for Net Income · Roquefort Therapeutics plc · 2022-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Net Income: -177096 GBP Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=GBP&dimensions= Input fundies:NetIncome: -177096 GBP (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2022-12-31/ESEF/GB/1/2138009EB25MJIULQO19-2022-12-31.zip#155771 Filing: 254900P4SISIWOR9RH34-2022-12-31-ESEF-GB-1 The citation records this snapshot. The page link may show a newer release later.	−GBP 1.58 million Exact value Exact value: -1577476 GBP 2022-01-01 – 2022-12-31: -1577476 GBP Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Roquefort Therapeutics plc · 2022-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Operating Cash Flow: -1577476 GBP Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=GBP&dimensions= Input fundies:OperatingCashFlow: -1577476 GBP (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2023-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2023-12-31.zip#2119059 Filing: 254900P4SISIWOR9RH34-2023-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.	GBP 0 Exact value Exact value: 0 GBP 2022-01-01 – 2022-12-31: 0 GBP Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Roquefort Therapeutics plc · 2022-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Capital Expenditure: 0 GBP Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=GBP&dimensions= Input fundies:CapitalExpenditure: 0 GBP (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2023-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2023-12-31.zip#2119930 Filing: 254900P4SISIWOR9RH34-2023-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.	−GBP 1.58 million Calculation and evidence -1577476 − 0 GBP Exact free cash flow: -1577476 GBP 2022-01-01 – 2022-12-31: -1577476 GBP · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 0 GBP · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Roquefort Therapeutics plc · 2022-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Free cash flow: -1577476 GBP Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1577476 GBP (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2023-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2023-12-31.zip#2119059 Filing: 254900P4SISIWOR9RH34-2023-12-31-ESEF-GB-0 Input fundies:CapitalExpenditure: 0 GBP (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2023-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2023-12-31.zip#2119930 Filing: 254900P4SISIWOR9RH34-2023-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	Unavailable Not reported for this period.	−GBP 1.73 million Exact value Exact value: -1733533 GBP 2023-01-01 – 2023-12-31: -1733533 GBP Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Roquefort Therapeutics plc · 2023-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Operating Cash Flow: -1733533 GBP Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=GBP&dimensions= Input fundies:OperatingCashFlow: -1733533 GBP (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3071402 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.	GBP 54,042 Exact value Exact value: 54042 GBP 2023-01-01 – 2023-12-31: 54042 GBP Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Roquefort Therapeutics plc · 2023-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Capital Expenditure: 54042 GBP Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=GBP&dimensions= Input fundies:CapitalExpenditure: 54042 GBP (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3072350 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.	−GBP 1.79 million Calculation and evidence -1733533 − 54042 GBP Exact free cash flow: -1787575 GBP 2023-01-01 – 2023-12-31: -1733533 GBP · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 54042 GBP · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Roquefort Therapeutics plc · 2023-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Free cash flow: -1787575 GBP Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1733533 GBP (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3071402 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 Input fundies:CapitalExpenditure: 54042 GBP (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3072350 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	Unavailable Not reported for this period.	−GBP 783,731 Exact value Exact value: -783731 GBP 2024-01-01 – 2024-12-31: -783731 GBP Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Roquefort Therapeutics plc · 2024-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Operating Cash Flow: -783731 GBP Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=GBP&dimensions= Input fundies:OperatingCashFlow: -783731 GBP (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3071106 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.	GBP 0 Exact value Exact value: 0 GBP 2024-01-01 – 2024-12-31: 0 GBP Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Roquefort Therapeutics plc · 2024-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Capital Expenditure: 0 GBP Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=GBP&dimensions= Input fundies:CapitalExpenditure: 0 GBP (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3072018 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.	−GBP 783,731 Calculation and evidence -783731 − 0 GBP Exact free cash flow: -783731 GBP 2024-01-01 – 2024-12-31: -783731 GBP · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 GBP · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Roquefort Therapeutics plc · 2024-12-31 Roquefort Therapeutics plc (esef:254900P4SISIWOR9RH34) Free cash flow: -783731 GBP Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T15:00:39Z Snapshot: 19f9e711939f3845da53e027cd348e92dfdb46ca028ac83ef8414db6a6d12e6b Dimensions: Consolidated View: https://fundies.io/companies/esef/254900P4SISIWOR9RH34?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -783731 GBP (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3071106 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 Input fundies:CapitalExpenditure: 0 GBP (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900P4SISIWOR9RH34/2024-12-31/ESEF/GB/0/254900P4SISIWOR9RH34-2024-12-31-en.zip#3072018 Filing: 254900P4SISIWOR9RH34-2024-12-31-ESEF-GB-0 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

4 filings · 287 latest values · 287 originally reported values

Dataset published 2026-11-09. Source filing dates and reporting periods are shown separately.

Identifiers: 254900P4SISIWOR9RH34, esef:254900P4SISIWOR9RH34

Roquefort Therapeutics plc

Latest fiscal year

Revenue

Net margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation